Compare Amgen, Inc. (AMGN) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Alexandria Real Estate Equities Inc — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B). The key difference: Amgen, Inc. is far larger — about 27.1× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| AMGN | ARE | |
|---|---|---|
Market Cap | $224.14B | $8.28B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $87.45 |
52-Week Low | $271.18 | $40.41 |
Enterprise Value | $267.45B | $20.98B |
Dividend Yield | 2.43% | 5.99% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →
